Nicholas T Bott1, Clifford C Sheckter2, Daniel Yang2, Stephanie Peters2, Brian Brady2, Scooter Plowman2, Soo Borson3, Bruce Leff4, Robert M Kaplan2, Terry Platchek2, Arnold Milstein2. 1. Clinical Excellence Research Center (NTB, CCS, DY, SP, BB, SP, RMK, TP, AM), Stanford University School of Medicine, Stanford University, Stanford, CA. Electronic address: nbott@stanford.edu. 2. Clinical Excellence Research Center (NTB, CCS, DY, SP, BB, SP, RMK, TP, AM), Stanford University School of Medicine, Stanford University, Stanford, CA. 3. the Department of Psychiatry and Behavioral Sciences (SB), University of Washington, Seattle; the Department of Neurology (SB), University of Minnesota, Minneapolis. 4. Center for Transformative Geriatric Research (BL), Division of Geriatric Medicine and Gerontology, Johns Hopkins University School of Medicine, Baltimore.
Abstract
OBJECTIVE: The authors describe a comprehensive care model for Alzheimer disease (AD) that improves value within 1-3 years after implementation by leveraging targeted outpatient chronic care management, cognitively protective acute care, and timely caregiver support. METHODS: Using current best evidence, expert opinion, and macroeconomic modeling, the authors designed a comprehensive care model for AD that improves the quality of care while reducing total per capita healthcare spending by more than 15%. Cost savings were measured as reduced spending by payers. Cost estimates were derived from medical literature and national databases, including both public and private U.S. payers. All estimates reflect the value in 2015 dollars using a consumer price index inflation calculator. Outcome estimates were determined at year 2, accounting for implementation and steady-state intervention costs. RESULTS: After accounting for implementation and recurring operating costs of approximately $9.5 billion, estimated net cost savings of between $13 and $41 billion can be accomplished concurrently with improvements in quality and experience of coordinated chronic care ($0.01-$6.8 billion), cognitively protective acute care ($8.7-$26.6 billion), timely caregiver support ($4.3-$7.5 billion), and caregiver efficiency ($4.1-$7.2 billion). CONCLUSION: A high-value care model for AD may improve the experience of patients with AD while significantly lowering costs.
OBJECTIVE: The authors describe a comprehensive care model for Alzheimer disease (AD) that improves value within 1-3 years after implementation by leveraging targeted outpatient chronic care management, cognitively protective acute care, and timely caregiver support. METHODS: Using current best evidence, expert opinion, and macroeconomic modeling, the authors designed a comprehensive care model for AD that improves the quality of care while reducing total per capita healthcare spending by more than 15%. Cost savings were measured as reduced spending by payers. Cost estimates were derived from medical literature and national databases, including both public and private U.S. payers. All estimates reflect the value in 2015 dollars using a consumer price index inflation calculator. Outcome estimates were determined at year 2, accounting for implementation and steady-state intervention costs. RESULTS: After accounting for implementation and recurring operating costs of approximately $9.5 billion, estimated net cost savings of between $13 and $41 billion can be accomplished concurrently with improvements in quality and experience of coordinated chronic care ($0.01-$6.8 billion), cognitively protective acute care ($8.7-$26.6 billion), timely caregiver support ($4.3-$7.5 billion), and caregiver efficiency ($4.1-$7.2 billion). CONCLUSION: A high-value care model for AD may improve the experience of patients with AD while significantly lowering costs.
Authors: Melonie Heron; Donna L Hoyert; Sherry L Murphy; Jiaquan Xu; Kenneth D Kochanek; Betzaida Tejada-Vera Journal: Natl Vital Stat Rep Date: 2009-04-17
Authors: Henry Michael Arrighi; Peter J Neumann; Ivan M Lieberburg; Raymond J Townsend Journal: Alzheimer Dis Assoc Disord Date: 2010 Jan-Mar Impact factor: 2.703
Authors: Gideon A Caplan; Nur S Sulaiman; Dee A Mangin; Nicoletta Aimonino Ricauda; Andrew D Wilson; Louise Barclay Journal: Med J Aust Date: 2012-11-05 Impact factor: 7.738
Authors: Gianluca Isaia; Marco A Astengo; Vittoria Tibaldi; Mauro Zanocchi; Benedetta Bardelli; Rossella Obialero; Alessandra Tizzani; Mario Bo; Corrado Moiraghi; Mario Molaschi; Nicoletta Aimonino Ricauda Journal: Age (Dordr) Date: 2009-01-30
Authors: Monica Cepoiu-Martin; Helen Tam-Tham; Scott Patten; Colleen J Maxwell; David B Hogan Journal: Int J Geriatr Psychiatry Date: 2016-04-04 Impact factor: 3.485
Authors: Danielle H Rochlin; Chuan-Mei Lee; Claudia Scheuter; Terry Platchek; Robert M Kaplan; Arnold Milstein Journal: Public Health Rep Date: 2020-09-22 Impact factor: 2.792